| Literature DB >> 31312257 |
Gordon J Hendry1, Linda Fenocchi1,2, Helen Mason2, Martijn Steultjens1.
Abstract
BACKGROUND: Multimorbidity is prevalent and adversely affects health outcomes. Foot pain is common and one of the primary reasons for utilisation of podiatry services. At present, little is known about the impact of multimorbidity on foot health and related outcomes following podiatric intervention. The aims of this study were to evaluate whether there is a difference in foot health outcomes following exposure to podiatric foot care for people with and without multimorbidity; and ii) to evaluate whether the presence or absence of multimorbidity affects patients' perceptions of change in foot pain.Entities:
Keywords: Comorbidity; Foot pain; Multimorbidity; Musculoskeletal; Podiatry
Mesh:
Year: 2019 PMID: 31312257 PMCID: PMC6609344 DOI: 10.1186/s13047-019-0346-x
Source DB: PubMed Journal: J Foot Ankle Res ISSN: 1757-1146 Impact factor: 2.303
Fig. 1Study participant flow chart
Demographics
| Whole sample | No condition | Single condition | > 1 Condition | |
|---|---|---|---|---|
| Number of participants, n (%) | 115 (100) | 26 (22.6) | 28 (24.3) | 61 (53) |
| Age in years, mean (SD) | 55 (11.56) | 53.4 (9.5) | 52.4 (12.8) | 56.95 (11.6) |
| BMI, median (IQR) | 29.9 (19.2) | 28.8 (19.7) | 27.7 (21.6) | 32.9 (17.8)† |
| Sex ratio (female:male) | 68:45 | 17:9 | 14:13 | 37:23 |
| EQ-5D-5 L Index, mean (SD) | 0.55 (0.31) | 0.73 (0.18) | 0.69 (0.17) | 0.42 (0.34) ‡‡ |
| EQ-5D-5 L VAS, mean (SD) | 66.69 (25.74) | 78.62 (18.72) | 75.3 (22.05) | 57.8 (26.75) ‡‡ |
| SIMD lowest 2 quintiles, n (%) | 48 (41.7) | 12 (46.2) | 7 (25) | 29 (47.5) |
| Employment status, n (%) | ||||
| Paid or self-employed full time | 39 (33.9) | 11 (42.3) | 14 (50) | 14 (23.0) |
| Paid or self-employed part time | 17 (14.8) | 4 (15.4) | 4 (14.3) | 9 (14.8) |
| Voluntary work | 1 (0.9) | 1 (3.8) | 0 | 1 (1.6) |
| Looking for work | 2 (1.7) | 7 (26.9) | 0 | 2 (3.3) |
| Student in further or higher education | 2 (1.7) | 1 (3.8) | 2 (7.1) | 0 |
| Looking after the home or family | 4 (3.5) | 1 (3.8) | 1 (3.6) | 2 (3.3) |
| Wholly retired | 30 (26.1) | 7 (26.9) | 6 (21.4) | 17 (27.9) |
| Permanently unable to work | 10 (8.7) | 1 (3.8) | 0 | 9 (14.8) |
| Other | 5 (4.3) | 1 (3.8) | 0 | 4 (6.6) |
| Prefer not to answer | 2 (1.7) | 0 | 0 | 2 (3.3) |
Mann-Whitney tests significant at ‡‡p < 0.01 for Single Condition versus > 1 conditions group comparison
Mann-Whitney tests significant at †p < 0.05 for No conditions versus > 1 conditions comparison
SD Standard deviation, IQR Interquartile range, BMI Body mass index, SIMD Scottish Index of Multiple Deprivation, n number of participants, EQ-5D-5 L EuroQoL 5 Dimensions 5 level questionnaire, VAS Visual analogue scale
Comorbidities
| Condition, n (%) | Diagnosed with condition | Receiving treatment for condition | Condition limits activities |
|---|---|---|---|
| Heart disease | 12 (10.4) | 10 (8.7) | 6 (5.2) |
| High blood pressure | 23 (20) | 18 (15.7) | 6 (5.2) |
| Lung disease | 11 (9.6) | 8 (7.0) | 4 (3.5) |
| Diabetes | 7 (6.1) | 4 (3.5) | 3 (2.6) |
| Ulcer/stomach disease | 13 (11.3) | 11 (9.6) | 6 (5.2) |
| Kidney disease | 3 (2.6) | 1 (0.9) | 2 (1.7) |
| Liver disease | 3 (2.6) | 1 (0.9) | 1 (0.9) |
| Anaemia or other blood disease | 10 (8.7) | 6 (5.2) | 6 (5.2) |
| Cancer | 6 (5.2) | 2 (1.7) | 2 (1.7) |
| Depression | 20 (17.4) | 11 (9.6) | 15 (13.0) |
| Osteoarthritis or degenerative arthritis | 38 (33.0) | 24 (20.9) | 32 (27.8) |
| Back Pain | 50 (43.5) | 22 (19.1) | 34 (29.6) |
| Rheumatoid or inflammatory arthritis | 9 (7.8) | 5 (4.3) | 6 (5.2) |
| Other medical problems | 44 (38.3) | – | – |
| Rheumatic or musculoskeletal diseasesa | 7 (6.1) | – | – |
| Neurological conditionsb | 9 (7.9) | – | – |
| Hypo/hyper thyroidism | 5 (4.4) | – | – |
| Asthma | 4 (3.5) | – | – |
| Sleep apnoea | 3 (2.6) | – | – |
| Other | 16 (13.9) | – | – |
agout, mixed connective tissue disease, Sjogren’s syndrome, ankylosing spondylitis, fibromyalgia, osteopenia, and benign hypermobility (all n = 1)
bstroke/transient ischaemic attack (n = 3), trigeminal neuralgia, multiple sclerosis, Parkinson’s disease, epilepsy, polio, and neuropathy (all n = 1)
N Number of participants
Baseline foot pain characteristics
| Whole sample ( | No condition ( | Single condition ( | > 1 condition ( | |
|---|---|---|---|---|
| Foot pain NRS 0–10, median (IQR) | 6 (4) | 5 (2.25) | 6 (2.75) | 8 (4) |
| Foot pain region, n (%) | ||||
| Hindfoot | 50 (43.5) | 8 (30.8) | 5 (17.9) | 37 (60.7) |
| Forefoot | 61 (53.0) | 15 (57.7) | 11 (39.3) | 35 (57.4) |
| Toes | 59 (51.3) | 9 (34.6) | 14 (50.0) | 36 (59.0) |
| Ball | 56 (51.3) | 12 (46.2) | 14 (50) | 30 (49.2) |
| Arch | 55 (47.8) | 9 (34.6) | 9 (32.1) | 37 (60.7) |
| Heel | 49 (42.6) | 13 (50.0) | 6 (21.4) | 30 (49.2) |
| Nails | 12 (10.4) | 1 (3.8) | 1 (3.6) | 10 (16.4) |
NRS Numerical rating scale, IQR Interquartile range, n number of participants
Podiatry treatments received over previous 6 months
| Podiatry treatments received over previous 6 months | Number of participants n (%) |
|---|---|
| Foot orthoses | 55 (47.83) |
| Footwear advice/modifications | 40 (34.78) |
| Medications | 32 (27.83) |
| Rest | 30 (26.09) |
| Exercises | 47 (40.87) |
| Physical therapies | 23 (20) |
| Acupuncture | 3 (2.61) |
| Othera | 30 (26.09) |
| Self-management | 22 (19.13) |
| Number of treatments received per patient (median, IQR) | 2 (2–3) |
aReferral (n = 5), steroid injection (n = 3), rocker boot, nail care, trans-electrical nerve stimulation, dome pad
N Number of participants, IQR Interquartile range
Group comparisons for FHSQ domains at baseline, 3 and 6 month follow-ups
| FHSQpain, median (IQR) | FHSQfunction, median (IQR) | FHSQfootwear, median (IQR) | FHSQhealth, median (IQR) | |
|---|---|---|---|---|
| Baseline | ||||
| No condition | 41.88 (43.13) | 62.5 (40.63)** | 41.67 (39.58) | 33.75 (38.13)** |
| Single condition | 41.25 (41.25) | 65.63 (31.25)**‡‡ | 37.5 (41.67) | 36.25 (44.38)**‡ |
| > 1 conditions | 29.38 (48.75) | 31.25 (53.13)**†† | 25.0 (39.58) | 25.0 (42.5)**†† |
| 3 months | ||||
| No condition | 60.63 (39.69) | 84.38 (28.13)** | 29.17 (31.25) | 42.5 (53.75)* |
| Single condition | 47.5 (46.25) | 87.5 (31.25)**‡‡ | 41.67 (58.33) | 60.0 (35.0)* |
| > 1 conditions | 35.0 (43.13) | 46.88 (64.06)**†† | 25.0 (54.17) | 25.0 (60.0)*† |
| 6 months | ||||
| No condition | 69.38 (26.09)* | 90.63 (21.88)** | 37.5 (52.08)* | 60.0 (66.25)* |
| Single condition | 44.69 (48.91)* | 87.5 (31.25)**‡‡ | 41.67 (50.0)* ‡‡ | 42.5 (60.0)* |
| > 1 conditions | 35.63 (48.91)*†† | 50.0 (59.38)**†† | 25.0 (45.83)* | 25.0 (51.25)*† |
Kruskall-Wallis tests significant at **p < 0.01 and *p < 0.05
Post-hoc Mann-Whitney tests significant at ‡‡p < 0.01 and ‡p < 0.05 for Single Condition versus > 1 conditions group comparison
Post-hoc Mann-Whitney tests significant at ††p < 0.01 and †p < 0.05 for No conditions versus > 1 conditions comparison
FHSQ Foot health status questionnaire, IQR Interquartile range
Fig. 2Median fhsq scores for comorbidity groups at 0, 3 and 6 months
Group comparisons for change scores for FHSQ domains between baseline and 3 months and baseline and 6 month follow-ups
| FHSQ pain, median (IQR) | FHSQ function, median (IQR) | FHSQ footwear, median (IQR) | FHSQ health, median (IQR) | |
|---|---|---|---|---|
| 0 to 3 months | ||||
| No condition | −6.26 (35.94) | − 6.23 (21.88) | 0 (22.91) | 0 (9.38) |
| Single condition | −5.63 (16.88) | −6.23 (21.88) | 0 (25.0) | 0 (21.25) |
| >1 conditions | −6.26 (13.76) | 0 (18.75) | 0 (33.33) | 0 (12.5) |
| 0 to 6 months | ||||
| No condition | −11.88 (45.0) | −18.75 (40.63) | 0 (43.75) | 0 (31.25) |
| Single condition | −1.57 (41.10) | −9.38 (25.0) | −8.33 (25.0) | 0 (37.5) |
| >1 conditions | −6.26 (22.81) | 0 (12.5) | 0 (25.0) | 0 (18.75) |
No significant differences between groups for changes scores, Kruskall-Wallis tests
FHSQ Foot health status questionnaire, IQR Interquartile range
Associations between multimorbidity and FHSQ pain and function domains
| Variable | FHSQ pain 3 months | FHSQ pain 6 months | ||||
| Unadjusted |
|
|
|
|
| |
| Multimorbidity | −17.95 (−32.92, − 2.99) | 7.53 | − 0.32* | −25.95 (− 41.68, − 10.23) | 7.90 | −0.48** |
| Single condition | − 11.13 (− 28.66, 6.40) | 8.82 | − 0.17 | − 18.20 (− 35.72,-0.68) | 8.80 | − 0.30* |
| Adjusted | ||||||
| Multimorbidity | −2.64 (− 13.98, 8.71) | 5.70 | − 0.05 | − 17.17 (− 31.02, − 3.31) | 6.94 | − 0.32* |
| Single condition | −3.35 (− 16.14, 9.45) | 6.42 | − 0.05 | − 13.61 (− 28.72, 1.16) | 7.40 | −0.23 |
| Baseline FHSQ pain | 0.85 (0.67, 1.04) | 0.09 | 0.77** | 0.63 (0.44, 0.83) | 0.10 | 0.60** |
| Age | − 0.35 (− 0.76, 0.06) | 0.21 | −0.14 | − 0.14 (− 0.57, 0.30) | 0.22 | −0.06 |
| BMI | 0.13 (−0.23, 0.49) | 0.18 | 0.06 | −0.01 (− 0.43, 0.41) | 0.21 | − 0.01 |
| Sex | − 0.11 (− 9.5, 9.30) | 4.72 | − 0.00 | −1.88 (− 12.57, 8.82) | 5.40 | − 0.03 |
| FHSQ function 3 months | FHSQ function 6 months | |||||
| Unadjusted |
|
|
|
|
| |
| Multimorbidity | −33.63 | 8.11 | −0.51** | −35.36 | 8.67 | −0.55** |
| Single condition | −5.36 | 9.48 | −0.07 | − 5.07 | 9.68 | −0.07 |
| Adjusted | ||||||
| Multimorbidity | −16.70 (−29.72, −3.67) | 6.54 | −0.25* | −21.71 (−34.02, −9.39) | 6.17 | − 0.34** |
| Single condition | −8.60 (− 22.34, 5.15) | 6.90 | − 0.11 | −10.84 (−23.93, 2.26) | 6.56 | − 0.16 |
| Baseline FHSQ function | 0.75 (− 0.28, 0.58) | 0.08 | 0.71** | 0.73 (0.58, 0.88) | 0.07 | 0.71** |
| Age | 0.15 (−0.28, 0.58) | 0.22 | 0.05 | −0.16 (− 0.55, 0.22) | 0.19 | − 0.06 |
| BMI | 0.03 (−0.35, 0.41) | 0.19 | 0.01 | −0.07 (− 0.43, 0.28) | 0.18 | − 0.03 |
| Sex | 3.98 (−5.86, 13.81) | 4.94 | 0.06 | 3.98 (−5.29, 13.22) | 4.64 | 0.86 |
FHSQ Pain 3 months, R2 = 0.06 for unadjusted, R2 = 0.56 for adjusted; FHSQ Pain 6 months, R2 = 0.12 for unadjusted, R2 = 0.46 for adjusted
FHSQ Function 3 months, R2 = 0.22 for unadjusted, R2 = 0.65 for adjusted; FHSQ Function 6 months, R2 = 0.25 for unadjusted, R2 = 0.69 for adjusted
Significant at **p < 0.01 and *p < 0.05
FHSQ Foot health status questionnaire, B Beta coefficient, SE β Coefficient standard error, β Standardised beta coefficient
Contingency tables for associations between multimorbidity group membership and PRCS improvement versus no change/deterioration
| No change/ deteriorated | Improved | Cramer’s V | ||
|---|---|---|---|---|
| 0 to 3 months ( | ||||
| No condition | 7 (35.0) | 13 (65.0) | 0.265 | 0.037* |
| Single condition | 11 (50.0) | 11 (50.0) | – | – |
| Multimorbidity | 35 (67.3) | 17 (32.7) | – | – |
| 0 to 6 months ( | ||||
| No condition | 4 (28.6) | 10 (71.4) | 0.29 | 0.032* |
| Single condition | 11 (47.8) | 12 (52.2) | – | – |
| Multimorbidity | 30 (66.7) | 15 (33.3) | – | – |
N Number of participants